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Abstract This Account describes the development of our cross-cou-
pling and medicinal chemistry research from its origins at the outset of
my independent career through to the present day. Throughout, the
decisions and motivations as well as the mistakes and pitfalls are dis-
cussed.
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1 Introduction
‘Scientists are generally good at finding solutions to prob-
lems. The biggest problem with starting a research program is
identifying a good problem.’ This is the piece of advice that I
remember most from the time when I was thinking of pro-
posals for my own independent career. It is fair to say that
this is also, ironically, the piece of advice that I found the
most problematic – pick a good problem. I’m fairly sure this
might resonate with some readers. Gauging a ‘good’ prob-
lem is an entirely subjective process and how good a prob-
lem is, or more accurately, how a scientific output is valued,
varies enormously. With regards to my own field, synthetic
chemistry, something that might seem ‘incremental’ to an
academic might be transformative for an end user across
disciplines (e.g., biologist). Equally, a major conceptual or
fundamental advance might be completely irrelevant from
a practical perspective. The escalating problems of trial by
impact factor as well as access to and polarization of fund-
ing adds a further problem to the mix and further pressure
on new principal investigators (PIs). The decision of what to
base an independent research program upon is absolutely a
problem.
At the time of writing, our group has been operating for
around eight years, which is, in my opinion, short enough
to remember the difficulties at the outset and long enough
to be able to reflect a little on some of the decisions and es-
pecially the failures, which, I would argue, is more valuable.
In this Account I’ll try to give an overview of some of the
projects we have been involved in, with some of the deci-
sions that affected the development of the research.
I would like to highlight at the outset that all of the work
reported here, as well as the wider catalogue of research we
have generated over the past eight years, is the product of a
series of very talented undergraduate, graduate, and post-
doctoral co-workers, as well as very generous (in time, tal-
ent, and resource) collaborators in academia and industry. I
have been fortunate to have been involved in this work, but
the outputs described in this essay are a testament to the
tenacity and ability of these co-workers and collaborators.
2 Hobbies and Interests
One of the most difficult things to do was to decide
what I was interested in. At least interested in enough to
write proposals on, bearing in mind that the proposal
should outline the widely sought ‘program of research’. (AsSynlett 2020, 31, A–O
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you are proposing something novel, something that has no
precedent in the literature, regardless of how robust the un-
derpinning fundamental scientific theory is, there remains
a risk that it won’t work. So, outlining 5+ years of research
on this untested concept seems more like an exercise in cre-
ative writing than anything else.) I enjoy a lot of different
chemistry and I especially enjoy making things, and the
possible utility of the arising products (I’m a big Lego fan
and also worked for a long time as a professional carpen-
ter), hence my focus on organic chemistry. The decision
over what eggs to put in the specific research program bas-
ket was a difficult one, but catalysis was an area that I
thought would allow our group to make possibly useful
products and develop potentially useful understanding.
3 Scooped before Starting
I thought I’d include this story as I think this is a fairly
common concern and/or experience for new PIs. During
grad school studies, I was involved in a project that involved
conjugate addition to a vinyl 1,2-4-oxadiazole1 (Scheme 1,
a), and in my postdoc I was involved in asymmetric organo-
catalysis, with one aspect being enantioselective conjugate
addition via iminium catalysis. The combination of these
was the essence of what was my first proposal – enantiose-
lective conjugate addition to vinyl heterocycles, which I had
thought of as being based on Hayashi-type Rh catalysis us-
ing organoborons (Scheme 1, b).2,3
Disaster struck, however, in the run up to applying for
positions with my newly minted set of proposals, when the
first example of this asymmetric conjugate addition (reduc-
tion in this initial case) was published by Prof. Hon Lam,4 at
the time at the University of Edinburgh, now at the Univer-
sity of Nottingham (Scheme 1, c).5 Over the last 10 years or
so, Prof. Lam has done remarkable things in this area using
several transition metals and novel ligand architectures, de-
veloping beautiful chemistry that is significantly beyond
anything I had imagined. So, a small consolation was that
the chemistry ended up in the best place with the best per-
son.
I reworked this proposal to focus on asymmetric pro-
tonation instead of conjugate addition, and we have recent-
ly published our first example of this approach (Scheme 2).6
Scheme 2  Chiral heterocycles via aza-Michael/asymmetric protonation
However, while it finally worked out, this journey has
not been smooth or easy: the first grant proposal for this
research was rejected, and it took seven years to piece to-
gether the resource to deliver the first paper. The ‘hang on
in there’ advice is easier to dispense than to accept but
there is, at least from the perspective of this project, some
value in it. It certainly hasn’t worked out for other projects,
and in terms of ‘academic growth’, I’d argue that knowing
when to kill a project, regardless of how attached you may
be to it, is very valuable (examples of this below).
Scheme 1  (a) Grad school research. (b) Proposal based on asymmetric 
conjugate addition to vinyl heterocycles. (c) First publication of an 
asymmetric conjugate addition (reduction) of vinyl heterocycles by 
Prof. Hon Lam.
(a) Conjugate addition to a vinyl 1,2,4-oxadiazole
(b) Proposal based on asymmetric conjugate addition to vinyl heterocycles
(c) First asymmetric conjugate addition to vinyl heterocycles (Lam, 2009)
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Before starting out as a PI, I completed a second postdoc,
this time in industry (GlaxoSmithKline, GSK). During this
time, I was fortunate to meet some great scientists. Beyond
the scope of this Account, we have had a long collaboration
in Sustainable Chemistry with GSK and which led to a long-
term collaboration with Sigma-Aldrich (now Merck KgA).7
To, finally, arrive at the subject of this Account, discus-
sions with scientists at GSK led to an idea for collaboration
on a medicinal chemistry project. Our collaborators were
likeminded with regards to how we thought industry and
academia could interact collaboratively and with the finan-
cial support of GSK and my department, we were able to re-
source a collaborative medicinal chemistry project.
A major target for GSK at that time was idiopathic pul-
monary fibrosis (IPF). To keep this new collaboration dis-
tinct, we constructed a project towards IPF intervention via
a peripheral target (i.e., not an active project at GSK).
This was initially based on development of antagonists
for LPA1, a member of a family of G-protein-coupled recep-
tors (GPCRs) termed LPA1–6. This signaling axis begins by
the hydrolysis of lysophosphatidyl choline (LPC) by the en-
zyme autotaxin (ATX; important later) leading to lysophos-
phatidic acid (LPA, Scheme 3). LPA is an agonist for LPA1–6
and leads to a signaling cascade that can promote, amongst
other effects, cell migration, proliferation, and survival.
Misregulation of this pathway has been implicated in sever-
al pathologies including, amongst others, autoimmune dis-
eases, cancer, and, the therapy area for the emerging collab-
oration, IPF.8
Scheme 3  Signaling axis targeted for the collaborative medicinal 
chemistry project
Medicinal chemistry is an expensive pursuit and, as a
new research group with limited resource, could have been
a serious problem to deliver. (Another aside: no biology re-
source was available in our labs or at GSK, so we had to de-
velop additional collaborations to deal with this key aspect
of the project – more on this later.)
In terms of where to start, looking into the chemical and
patent literature in this area, a patent by Amira pharmaceu-
ticals stood out. AM095 and AM966 (Figure 1) were attrac-
tive as they are simple to build, which would allow straight-
forward synthesis and generation of chemical matter for
scaffold-hopping structure–activity relationships (SAR).9
Figure 1  Structure of AM095 and AM966
Perhaps more importantly, AM095 and AM966 could be
built via Suzuki–Miyaura cross-coupling. At the same time
the medicinal chemistry project was beginning, we also had
an interest in boron chemistry, in particular ligand ex-
change at boron (speciation), as well as chemoselectivity in
cross-coupling. A scaffold-hopping campaign based on the
Amira compounds offered the opportunity to investigate
boron speciation/chemoselective Suzuki–Miyaura cross-
coupling whilst targeting scaffolds of relevance to the me-
dicinal chemistry project. From my perspective this was as
close to ideal as a research program could be: it enabled
fundamental catalysis to be aligned with specific applica-
tion. It also allowed the catalysis-focused members of the
group to engage more effectively with the medicinal chem-
ists and vice versa, and additional benefits of maximizing
resources – suitable chemical matter from the catalysis
methodology work could be assessed in assays as possible
LPA1 antagonists, generating additional SAR.
5 Chemoselective Suzuki–Miyaura Cross-
Coupling
Using AM095 as a workhorse, retrosynthesis gives a
straightforward Suzuki–Miyaura disconnection (Scheme 4).
Scheme 4  (a) Suzuki–Miyaura approach to AM095. (b) Sequential che-
moselective Suzuki–Miyaura cross-coupling.
Alternative placements of the electrophilic and nucleo-
philic functional groups were of course possible, and use of
protected organoboron groups was also possible if, for ex-
ample, a dinucleophile was to be used in place of the dielec-
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remained – was it possible to perform two Suzuki–Miyaura
cross-couplings in a single operation?
From the components in Scheme 4 (a), the conventional
approach would be to undertake a single cross-coupling us-
ing one organoboron with the dielectrophile (Scheme 4, b,
top). The dielectrophile would require a sufficient reactivi-
ty gradient between the electrophilic sites (e.g., 1-bromo-4-
chlorobenzene) such that a suitable catalyst would selec-
tively engage the most labile C–X bond. Isolation of this in-
termediate would then allow a second cross-coupling with
a second organoboron, using a different catalyst capable of
engaging the remaining, less reactive, electrophilic site.
As noted above, the challenge we identified was to be
able to do all of this in a one-pot operation without any in-
tervention, which would require simultaneous control of
two electrophiles and two nucleophiles (Scheme 4, b, bot-
tom). Electrophile chemoselectivity was well established
and we assumed this would be relatively straightforward
based on established reactivity patterns and knowledge of
ligand effects in Pd catalysis.
The key phrase here is ‘assumed’. While it was well-
known that chemoselective cross-coupling is possible with
two (and more) electrophilic sites in a system, these pro-
cesses only engage (i.e., react) one site at a time. Use of a
single catalyst to sequentially and selectively engage two
inequivalent nucleophilic sites was, to our knowledge, un-
precedented. For example, in a system containing two
equivalent electrophilic sites, it was possible to either pro-
mote a single cross-coupling or exhaustive cross-coupling
(e.g., Scheme 5, a).10–12 Use of inequivalent dielectrophiles
had at that time only been reported to undergo selective
single cross-couplings, for example, the seminal work of Fu
(Scheme 5, b).13 An excellent review of this area was pub-
lished by Spivey and co-workers.14
Scheme 5  (a) Single (mono-) or exhaustive (bis-) cross-coupling of 
equivalent dielectrophiles by Sherburn. (b) Chemoselective single cross-
coupling of inequivalent dielectrophiles by Fu.
While challenges were at least clear from the electro-
phile side, things were less simple from the nucleophile
perspective. Cross-coupling in a system containing two or-
ganoborons, at the time, had been achieved only through
the use of protecting group chemistries, and these process-
es again only coupled one site (the protected organoboron
remaining intact). Specifically, for aryl organoborons, the
use of the base-labile BMIDA has been extensively devel-
oped by Burke15 (e.g., Scheme 6, a16) based on the work of
Mancilla and co-workers in the 1980s,17 or the acid-labile
BDAN protecting group developed by Suginome (e.g.,
Scheme 6, b18).19 Other excellent work in the area of selec-
tive Suzuki–Miyaura cross-coupling exploiting reactivity of
alkyl diboron systems has been reported by Shibata,20
Morken,21 Hall,22 Crudden,23 and others – an excellent re-
view of this area was published by Crudden.24,25
Scheme 6  (a) Use of the MIDA protecting group in Suzuki–Miyaura 
cross-coupling. (b) Use of the DAN protecting group in Suzuki–Miyaura 
cross-coupling.
To achieve our planned sequential cross-coupling, the
system would require two organoborons that were reactive
towards transmetalation. This suggested nucleophile selec-
tivity based on kinetic discrimination at transmetalation.
To this end, Hartwig demonstrated that arylboronic acids
transmetalate to (HO)(aryl)Pd(II) complexes ca. 30 times
faster than the equivalent arylboronic acid pinacol ester
(BPin).26 Based on this, a system containing an arylboronic
acid and aryl BPin may then seem like an ideal starting
point for investigating this process; however, we were
aware of issues relating to speciation that seemed likely to
obviate any possible kinetic advantage of the arylboronic
acid. Specifically, a 1:1 mixture of boronic acid 1a and BPin
2b will rapidly equilibrate to generate two different boronic
acids (1a and 2a) and their associated BPins (1b and 2b;
Scheme 7).27 Clearly we’d have little chance of achieving se-
lectivity if these processes took place during the desired re-
action.
Scheme 7  Equilibration of Ar1B(OH)2 and Ar2BPin
(a) Mono- or bis-Suzuki–Miyaura cross-coupling dependent on electrophile (Sherburn)
(b) Chemoselective Suzuki–Miyuara cross-coupling of dielectrophiles 
      with catalyst-based selectivity (Fu)
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planned a reaction that allowed us to investigate whether
some speciation control was possible, establishing a formal
C(sp2)BPin homologation process by leveraging aspects of
BMIDA chemistry (Scheme 8). Here, an aryl BPin would be
cross-coupled with a haloaryl BMIDA to generate a new aryl
BPin. The process would take place by exploiting several
base-promoted events, taking advantage of the usually ba-
sic reaction conditions associated with Suzuki–Miyaura
chemistry. The initial cross-coupling of 3 and 4 would gen-
erate BMIDA adduct 5 as well as the byproduct from this
cross-coupling, HOBPin (assuming that ArBPin undergo di-
rect transmetalation). Base-mediated hydrolysis of both of
these species would liberate the parent boronic acid 6a and
pinacol. These would then undergo esterification leading to
the desired product 6b. Several pieces of information sug-
gested that this all would be feasible in principle, including
Burke’s slow release of boronic acids from BMIDA species28
and that esterification of arylboronic acids with diols at ba-
sic pH is well-known in saccharide sensing, with significant
information on binding affinities, etc., available from nu-
merous studies in this field.29
Scheme 8  Design plan for a formal homologation of C(sp2)BPin based 
on controlled boron speciation
Despite this information, there were problems associat-
ed with this chemistry. Specifically, controlling the rate of
BMIDA hydrolysis:30 if either or both of the BMIDA starting
material 4 or intermediate biaryl BMIDA 5 were to undergo
hydrolysis before the Suzuki–Miyaura process was com-
plete, oligomerization would occur. Indeed, this was the
major issue faced with this methodology development;27,31
however, appropriate balance of the base:H2O ratio in the
system allowed effective control, enabling realization of a
general method for this BPin synthesis (Scheme 9, top). As a
side note, the BPin process required heating to 90 °C; the
same reaction conditions at room temperature allowed re-
tention of the BMIDA, demonstrating that the BMIDA unit
can tolerate basic conditions, at least in some cases
(Scheme 9, bottom).27,32
Scheme 9  Formal homologation of C(sp2)BPin: Example scope
At the time, we knew that we needed very dry Suzuki–
Miyaura conditions – 3 equiv K3PO4 and 5 equiv H2O.27,31a
While we documented the effects of base and H2O on this
specific system, we had only empirical evidence for these
effects: too little H2O led to poor cross-coupling, too much
led to rapid BMIDA hydrolysis and oligomerization issues.
Besides the oligomerization issue, we found that these con-
ditions facilitated a very fast Suzuki–Miyaura reaction,
which struck us as odd especially considering the that the
majority of Suzuki–Miyaura reactions are often conducted
using water as co-solvent or aqueous base; however, track-
ing down why this was the case came later (vide infra).
This initial system was a first step towards sequential
cross-coupling. We had shown it was possible to use two
organoborons (one protected as a BMIDA) and one electro-
philic site to generate a new C–C bond as well as a new and,
importantly, reactive organoboron site. With this estab-
lished, we sought to combine the nucleophile control with
electrophile control. The design was essentially an exten-
sion of the initial protocol (Scheme 10).31a
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system would allow (i) an initial electrophile-selective Su-
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cation events to generate a new BPin 6b, and (iii) a second
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the newly formed BPin to deliver the desired selectively
coupled product 8. Clearly, to achieve the electrophile con-
trol, C–X1 must be more labile than C–X2.
Based on what we had learned from the homologation
process, control of the hydrolytic events was relatively
straightforward from a practical sense – we had to control
the base:H2O stoichiometry (interestingly, note the higher
loadings of both vs. the homologation process – this was
necessary otherwise the second Suzuki–Miyaura stalled).
The electrophile chemoselectivity was realized purely via
focused ligand screening. ‘Focused’ here meaning assessing
ligands that were known to engage aryl chlorides. Ultimate-
ly, this process came to fruition, allowing a first example of
sequential chemoselective Suzuki–Miyaura cross-coupling
(Scheme 11).33
This sequential Suzuki–Miyaura process was effective
and certainly allowed construction of the two C–C bonds
important to the LPA1 antagonist campaign. However, with
regards to sequential cross-coupling based on control of ox-
idative addition and transmetalation, it was, essentially, a
bit of a cheat as we continued to rely upon a protecting
group strategy. This left work to be done.
Based on everything we had learned regarding con-
trolling boron speciation by this stage, we endeavored to
provide an answer. Returning to Hartwig’s observations of a
faster transmetalation of ArB(OH)2 to (HO)(aryl)Pd(II) com-
plexes vs. the equivalent ArBPin,26 we queried whether this
would be observed in a practical sense, i.e., in competition.
Charting the reaction profile (conversion into product)
of a simple Suzuki–Miyaura reaction using either boronic
acid 2a or the equivalent BPin 2b with bromobenzene inde-
pendently (under our preferred high base, low-water Suzu-
ki–Miyaura conditions), demonstrated that the initial rates
and overall reaction profiles were more or less identical, i.e.,
krel ca.1 (Scheme 12, a).34
However, the equivalent competition experiment under
the same reaction conditions told a very different story
(Scheme 12, b): while the reactivity of boronic acids and
the equivalent BPin appeared equivalent in isolation, they
were notably inequivalent in competition, with the boronic
acid 10a outcompeting the BPin 2b in the cross-coupling
with a selectivity of ca. 8:1 with krel ca. 10 in favor of the
Scheme 10  Design plan for a sequential chemoselective Suzuki–Mi-
yaura cross-coupling
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inate between the two different boron species at trans-
metalation (again, this was based on the reasonable as-
sumption that ArBPin undergo direct transmetalation).
A brief optimization of the reaction conditions resulted
in a general process where ArB(OH)2 underwent chemose-
lective cross-coupling in the presence of ArBPin (Scheme
13, a).34
Scheme 13  Sequential chemoselective Suzuki–Miyaura cross-coupling 
based on kinetic control of oxidative addition and transmetalation. (a) 
Example of chemoselectivity in a simple system. (b) Example of a two-
electrophile/two-nucleophile coupling to give two products. (c) Exam-
ple of a two-electrophile/two-nucleophile coupling to give a single 
product.
This then allowed the natural extension of the process
to deliver a chemoselective, sequential Suzuki–Miyaura
cross-coupling using two reactive electrophiles and two re-
active nucleophiles to give either a product pair, such as 13
and 14 (Scheme 13, b), or a single product (Scheme 13, c).
The boronic acid selectivity was, as far as we could tell, per-
fect in the competition experiments (Scheme 13, a); how-
ever, it was less than perfect in the sequential cross-cou-
pling (Scheme 13, b and c), where some erosion was detect-
ed. To sum up this section, these investigations showed that
sequential Suzuki–Miyaura cross-coupling was possible;
however, from a practical perspective, the better method is
the process outlined in Scheme 11, where controlling the
BMIDA hydrolysis events provide an additional control to
enforce chemoselectivity.33
6 Applications to the Medicinal Chemistry 
Campaign
Beyond IPF, our group has had interests in several other
areas of medicinal chemistry, including epigenetics.32,33,35
As a small demonstration of utility in this area, the BMIDA-
based sequential cross-coupling process was used to pre-
pare a pan-BET bromodomain inhibitor (Scheme 14).33
Scheme 14  Synthesis of pan-BET bromodomain inhibitor via sequen-
tial chemoselective Suzuki–Miyaura cross-coupling
However, and rather unfortunately, despite being an in-
spiration for the development of the methodology, the utili-
ty of these cross-coupling methods within our LPA1 antago-
nist program was decidedly short lived. Guidance from our
biological collaborators suggested the development of LPA1
antagonists was likely to be difficult based on high cell-sur-
face concentrations of LPA – arising due to the chaperone
effect of ATX.8 The guidance at this stage was that ‘moving
up a level’ in the signaling axis would be strategically sensi-
ble and have a greater likelihood of success. In other words,
instead of competing with LPA for the GPCRs, we would be
best interfering with the supply of LPA at source by devel-
oping inhibitors for ATX.
Despite this, we were successful in developing a novel
LPA1 antagonist scaffold, 15, which displayed moderate po-
tency (Figure 2).36 However, this was as far as the LPA1 story
progressed. Throughout the process we learned a great deal
from a scientific perspective – in both areas – and, from a
personal viewpoint, learning to let go of a project was cer-
tainly valuable.
Figure 2  LPA1 antagonist scaffold developed
7 Autotaxin and Heterocycle Synthesis
Moving to target ATX was a good decision. It was a dis-
crete molecular target and structurally enabled (i.e., there
was a crystal structure and knowledge of the active site).37
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importantly at the outset, there was patented chemical
matter that, similar to the LPA1 project, gave us a reasonable
place to start. In particular, there were assets from Amira38
(16) and Pfizer39 (PF8380) that provided interesting, and
seemingly feasible, objectives (Figure 3).
Figure 3  Structures of the ATX assets selected from Amira and Pfizer
Perhaps unsurprisingly, the majority of ATX inhibitors
developed at the stage we entered this area conformed to
the lipid-like chemotype, i.e., they resembled the structure
of the endogenous ligands LPC and LPA.8 The Pfizer lead,
PF8380, was a particularly potent compound (ca. 4 nm) and
from a structural perspective, much like the criteria for se-
lection of the starting points for the LPA1 project, this was
simple to assemble. From the medicinal chemistry perspec-
tive, there was little in the way of meaningful SAR with
PF8380 and no crystal structure of PF8380 bound in ATX.
This latter point was significant as it formed the basis of an
incredibly valuable collaboration with superb team of
structural biologists at the National Cancer Institute in The
Netherlands (NKI). Without the NKI team, this ATX project
would not have been anywhere near as successful. Apart
from providing all of the structural biology, the NKI team
also delivered all of the ATX assay data. Solving the ATX-
PF8380 structure was an initiation point for conversations,
which led to a significant collaboration on ATX. Accordingly,
PF8380 was an ideal compound to investigate in many re-
spects.
The Amira compound 16 was a slightly different story.
Significantly, the structure does not conform to the lipid-
like chemotype and so it was intriguing from that perspec-
tive. Despite being reported to be a potent compound (Ki
<0.3 M), the patent data was ‘binned’ into three categories
– Ki > 1 M, 0.3 > Ki < 1 M, and Ki < 0.3 M – meaning there
was very little by way of SAR for this compound.38 In addi-
tion, while PF8380 was a potent compound, it suffered
some significant solubility issues. Compound 16, however,
offered greater solubility combined with unique structural
qualities, such that we considered it significantly ‘more de-
velopable’. In other words, had a greater chance for explora-
tion of topological space to develop our own asset based on
a similar chemotype. This required SAR knowledge.
We duly undertook the unexpectedly challenging syn-
thesis of a small library of compounds based on 16, which
were evaluated in ATX assays to establish SAR.40 The syn-
thetic route to an exemplar compound in the library (18) is
shown in Scheme 15. The main issues with the route were
(i) the Fisher indole synthesis, which was not only low
yielding (around 35% overall yield) but delivered a ca. 3:1
mixture of regioisomers 17a and 17b that were difficult to
resolve (and only 17b required), and (ii) the penultimate
Ullmann–Goldberg step which was also very low yielding
(ca. 30%).
Scheme 15  Example of the route to Amira ATX SAR series
Despite the hurdles in the synthetic campaign, a mean-
ingful library was prepared. The SAR told us a reasonable
story and, coupled with some modelling data that aligned
with the assay data, this was certainly believable. However,
structural biology put all of this to rest. Co-crystals of 16-
ATX revealed that the compound didn’t bind in the active
site but rather bound in a region called the ‘tunnel’, which is
remote from the active site. Perhaps unsurprisingly, follow-
up Michaelis–Menten and Lineweaver–Burk studies estab-
lished that 16 was a noncompetitive inhibitor of ATX. Bind-
ing of similar compounds to the tunnel region was reported
at approximately the same time by two other research
groups.41,42
This inarguable biological data meant that we had, once
again, to walk away from a project, in this case to move on
from the idea that 16 was a reasonable starting point for
scaffold hopping and subsequent development.
Before moving on, I thought I’d illustrate how we
planned to use 16 as a starting point for our own discovery,
as this led to some new synthetic chemistry. As noted brief-
ly above, the synthesis of the library used for SAR on 16 was
not trivial. Besides the synthetic campaign around estab-
lishing SAR, we developed chemistry that would allow us to
make a series of substituted indoles more easily. Function-
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control the functionality and regiochemistry around the
benzenoid ring was important to our objectives. The direct
C2-functionalization of indoles, in the various ways that
this is possible, was not ideal for our purposes. Ultimately,
we designed some chemistry based on the Cacchi reac-
tion43,44 using a borylated alkyne (Scheme 16).7i,45
This would allow the indole to be built, controlling the
functionality on the benzenoid ring as well as the substitu-
tion (or, here, the lack of) at C3 and, in terms of added value
from a general synthetic methods perspective (in our opin-
ion), installed a BMIDA unit in the C2 position.
From the medicinal chemistry perspective, this would
allow us access to a range of useful compounds fairly rapid-
ly. However, the structural biology and kinetic data arrived
while we were establishing these methods, meaning they
were no longer necessary for this specific purpose. Howev-
er, this didn’t diminish the general synthetic value of the
method, which is an effective approach to 2-borylated in-
doles and benzofurans, as well as other fused heterocycles
(Scheme 17, a).7i,45 Apart from cross-coupling processes us-
ing the BMIDA, these compounds can be oxidized fairly eas-
ily to give access to 2-oxindoles, another important phar-
macophore (Scheme 17, b).46
Importantly, in addition to oxidation, the BMIDA per-
formed the functions that would be expected. Specifically,
Suzuki–Miyaura cross-coupling was straightforward to ei-
ther use the BMIDA as the nucleophilic component (Scheme
18, a) or retain in couplings of other sites (Scheme 18, b), or
during other chemistries, such as hydrogenation and Chan–
Lam amination (Scheme 18, c).45
Scheme 18  Example manipulation of 2-BMIDA indoles
8 ATX Hybrids and Pd(II) Speciation
Returning to the medicinal chemistry, the Amira project
was discontinued; however, the concurrent PF8380 project
started delivering some interesting results. Following
preparation of PF8380 (synthetic route shown in Scheme
19), our structural biologist collaborators solved the struc-
Scheme 16  Cacchi approach to 2-borylated indoles
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Scheme 17  (a) Cacchi’s approach to 2-BMIDA heterocycles: Example 
scope. (b) Oxidation of 2-BMIDA indoles to 2-oxindoles: Example scope.
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pected observation (Figure 4).47
A percentage of the crystals were found to have a bile
acid – UDCA or TUDCA – bound in the tunnel region along
with PF8380 in the active site. Perhaps unsurprisingly,
these bile acids are noncompetitive modulators of ATX
(similar to the Amira compound 1640). This offered an inter-
esting opportunity: we believed that a novel series of ATX
inhibitors could be generated through creation of a hybrid
series of compounds containing elements of the bile acid
and PF8380 (Scheme 20).
Scheme 20  Approach to hybrid ATX inhibitors
We considered this approach to be attractive from three
perspectives: (1) parallel studies indicated that the benzox-
azolidinone head group of PF8380 was the main contribu-
tor to the physicochemical property problems of this mole-
cule – the hybrid compounds would lack this motif; (2)
since the bile acid occupies the tunnel region and the di-
chloroarene occupies the lipophilic pocket, it would not be
possible for the enzyme to accommodate LPC (or any other
sizeable ligand) possibly turning a noncompetitive modula-
tor (the bile acid) into a competitive inhibitor; and (3) if
correct, this would represent a new class of ATX inhibitor,
giving some possible IP space.
To explore this, we created a series of hybrid com-
pounds based on the bile acid joined to the dichloroarene
via a series of linkers. The general synthetic route is shown
in Scheme 21 alongside selected compounds from this se-
ries.47
Scheme 19  Synthetic route to PF8380
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amples from the series
This approach proved very successful: the hybrid strate-
gy did indeed change the mode of action of the bile acids
from noncompetitive to competitive and, moreover, these
were potent compounds. This initial investigation formed
the basis for further development studies based on this
chemotype, which won’t be discussed here. However, in a
last foray into the chemistry inspired by this project, we
recognized a challenge in development of this series. We
had some information on chemotypes that bind in the tun-
nel, such as Amira compound 16, related compounds dis-
closed at around the same time, and the bile acids; howev-
er, a systematic exploration of this region was lacking.
Sticking with our hybrid series, establishing the mini-
mum determinants of potency was considered important to
further development work. This then became an exercise in
a classic problem for synthetic chemistry – how to build
steroid scaffolds. Moreover, a bigger synthetic challenge
was in play here – how to systematically explore SAR on
steroid scaffolds.
Before launching a potentially very resource intensive
synthetic chemistry project, we realized we might be able
to offer some advantage by again leveraging our interests in
speciation. Specifically, based on our work with the Suzuki–
Miyaura reaction, we became interested in the possibility of
controlling chemoselectivity by controlling Pd(II) specia-
tion. The fundamental project we envisaged was based on
selective cross-coupling of vinyl BPin (Scheme 22).48,49
Scheme 22  Chemoselective cross-coupling of vinyl BPin
Vinyl BPin is a competent nucleophile for Suzuki–Mi-
yaura cross-coupling and can undergo Mizoroki–Heck reac-
tions at the terminal carbon.50 Importantly, these two pro-
cesses are driven by two different Pd(II) species: the Suzu-
ki–Miyaura reaction is driven by (Ar)Pd(II)OH complexes
(oxopalladium pathway)26,51–53 while the Mizoroki–Heck is
driven by (Ar)Pd(II)X (where X = (pseudo)halide) and these
complexes are in an equilibrium. On the fundamental level,
we were interested in whether we could manipulate this
equilibrium effectively to allow selectivity for Suzuki–Mi-
yaura or Mizoroki–Heck.
Studies by Amatore and Jutand,51 Denmark,52 and
Hartwig26 had provided a significant body of data regarding
transmetalation during Suzuki–Miyaura cross-coupling via
oxopalladium species.53 Importantly, Hartwig provided use-
ful detail on Pd(II) anion metathesis including equilibrium
constants for OH→X exchange of (R3P)2Pd(Ar)(OH) com-
plexes.26 Based on our previous work in boron speciation
and with knowledge of the importance of H2O and base
within these processes, we probed the impact of H2O and
base on OH→X exchange for an exemplar Pd(II) complex
(19a). A snapshot of this data is provided in Scheme 23
showing that there is also a clear impact of base and water
on the equilibrium between (Ar)Pd(II)X complex 19a and
(Ar)Pd(II)OH complex 19b.48
Scheme 23  Pd(II) speciation influenced by H2O and base
The data suggested, perhaps counterintuitively, that
ArPd(II)OH complexes are in higher concentration under
drier conditions (i.e., with less H2O in the reaction mixture),
which was in agreement with Hartwig’s data.26 From our
perspective this was significant and assisted in making
sense of some previous observations in our boron specia-
tion work. Lloyd-Jones had previously established that the
boronic acid–boronate equilibrium favors the boronic acid
when the system is drier.54 Accordingly, a drier reaction fa-
vors both the neutral boronic acid and the Pd(II)OH com-
plex, both of which are required for transmetalation via the
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observations from our boron speciation work, where dry
conditions seemed to favor a ‘fast’ Suzuki–Miyaura reac-
tion.
Optimization allowed us to develop a system where
chemoselective cross-coupling of vinyl BPin was achieved
using the same reaction conditions by variation of the base
– K3PO4 for Suzuki–Miyaura and Et3N for Mizoroki–Heck
(Scheme 24).48
Scheme 24  Chemoselective cross-coupling of vinyl BPin: Example scope
From the synthetic perspective, we realized that if we
could achieve this in a reaction containing three different
olefins then we might be able to deliver a system that al-
lows selective cross-coupling of vinyl BPin to deliver a diene
that would undergo Diels–Alder reaction to give cyclo-
hexenes (Scheme 25).48,55 Depending on whether the reac-
tion proceeded via Mizoroki–Heck or Suzuki–Miyaura, the
cyclohexene product would be borylated or nonborylated,
respectively.
Scheme 25  Proposed application of the chemoselective BPin coupling
In the context of the steroid SAR, this wouldn’t answer
that question; however, this approach offered the possibili-
ty of generating a lot of information by allowing access to a
library of carbocycles, with broad variation of structure,
that we could use to explore the binding more broadly – es-
sentially a hit finding approach.
The physical-organic aspects of the Pd project are not
discussed here, but the process was successful, and we were
able to develop the desired chemoselective cross-cou-
pling/Diels–Alder processes to deliver a small library of ex-
emplar compounds (Scheme 26).48
Scheme 26  (a) Suzuki–Miyaura/Diels–Alder approach: Example scope. 
(b) Mizoroki–Heck/Diels–Alder approach: Example scope
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by this approach was fairly broad and importantly, the bor-
ylated compounds could be functionalized in the expected
ways (e.g., Scheme 27). We hope to report on the outcome
of these studies, in terms of the impact this chemistry has
had on our ATX program, in due course.
Scheme 27  Functionalization of example borylated compound 20
9 Conclusions
Hopefully, I have managed to take you on an honest tour
of how this research came to be and the twists and turns of
a new PI. Perhaps the biggest retrospective question, based
on the opening sentences, is ‘Did we pick a good problem?’
I have no idea. We picked a problem: a problem we were
interested in, a problem that we thought allowed us to ex-
plore as much of what we were interested in and within the
limits applied by the resources we had, and tried as best we
could to navigate our way through the issues we faced on
the way. I do believe we have offered something useful in
two main areas – new knowledge in boron chemistry and
Pd catalysis as well as in the medicinal chemistry area. We
– and personally speaking, I – learned a lot. A lot about var-
ious aspects of science, collaboration, project management,
and more. Would – or should – we have pursued anything
differently? Maybe. It’s probably natural to suggest that, if
given another go, we would have avoided making mistakes.
The question then becomes would we have learned as much
if we didn’t make these mistakes? I very much doubt it.
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